FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates

Study summary

Pulmonary infiltrates frequently complicate the care of hematopoietic stem cell transplant (HSCT) and leukemia patients. Bronchoalveolar lavage (BAL) is frequently used to evaluate new pulmonary infiltrates in this population, however utility is limited by a historically low diagnostic yield for infection. In an effort to improve diagnostic yields, this study will complete a Fiberoptic Bronchoscopy (FOB) within 8 hours of radiographic documentation of pulmonary infiltrates, prior to initiating new antibiotic therapy. To further improve detection of microbiological pathogens, the study will utilize PCR testing with rapid turnaround time to detect atypical pneumonia (M pneumoniae, C. Pneumonia, Legionella species, and respiratory viruses) and aspergillosis.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedMicrobiological analysis

The study team can explain what participation involves.

Who it may be forPulmonary Infiltrate New

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jul 11, 2017 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Northside Hospital, Inc.

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Not applicable
Sponsor: Northside Hospital, Inc.
Interventions being studied: Other: Microbiological analysis

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Autologous or allogeneic stem cell patients with new acute respiratory symptoms or pulmonary infiltrates
leukemia patients with new acute respiratory symptoms or pulmonary infiltrates thought to be unrelated to disease

Reasons someone may not be able to joinExclusion criteria

Patients unwilling to undergo FOB
Patients unable to undergo FOB due to clinical status
Patients unable to undergo FOB within 8 hours of radiographic report of pneumonia
Patients unable to wait until completion of FOB to implement antibiotic changes
Adults unable to provide informed consent

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Northside HospitalAtlanta, Georgia

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 11, 2017. Always confirm current availability with the study team.

View original record ↗